This Viewpoint describes reforms to the ways the National Health Service (NHS) appraises cost-effectiveness and coverage of cancer drugs in England and Wales, the role of the National Institute for Health and Care Excellence (NICE) in the process, and changes in drug approval rates and access to new drugs as a result.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2BIhWGd
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Many different quantitative techniques have been developed to either assess Environmental Justice (EJ) issues or estimate exposure and dose ...
-
Leddsmerter kan ha mange årsaker. Traumatiske, immunologiske og infeksiøse lidelser må vurderes. En god anamnese kan sette oss på rett spor...
-
Outcomes of Drug-Induced Sleep Endoscopy-Directed Surgery for Pediatric Obstructive Sleep Apnea. Otolaryngol Head Neck Surg. 2017 Nov ...
-
Evidence-Based Medicine: Cleft Palate. Plast Reconstr Surg. 2017 Jan;139(1):191e-203e Authors: Woo AS Abstract LEARNING OBJECTIVES:...
-
Apple, Facebook, Google and Microsoft claim the president’s ban on people from seven Muslim-majority countries inflicts "substantial ha...
-
Publication date: January 2017 Source: The Journal of Emergency Medicine, Volume 52, Issue 1 Author(s): Mariana Guerrero from #Alexa...
-
Abstract An intriguing piece of evidence for the inflammatory story of type 2 diabetes has come to the light. A recent study by Okin and co...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου